Ryan Deschner Analyst PerformanceAnalyst at UBS GroupRyan Deschner is a stock analyst at UBS Group in the healthcare sector, covering 14 publicly traded companies. Over the past year, Ryan Deschner has issued 20 stock ratings, including strong buy, buy, and hold recommendations. While full access to Ryan Deschner's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Ryan Deschner's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access to unlock analyst rankings MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings35 Last 1 YearsBuy Recommendations93.94% 31 Buy RatingsCompanies Covered14 Unique Companies Ratings Distribution33RatingsDistribution of strong buy, buy, hold, and sell ratings by Ryan Deschner.RatingPercentageCount Strong Buy57.6%19 ratings Buy36.4%12 ratings Hold6.1%2 ratings Sell0.0%0 ratingsOut of 33 total stock ratings issued by Ryan Deschner at UBS Group, the majority (57.6%) have been Strong Buy recommendations, followed by 36.4% Buy and 6.1% Hold.Best & Worst CallsBest Call0000.0%PVLAAug 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%TVRDJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ14 companiesRyan Deschner, an analyst at UBS Group, currently covers 14 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare14 companies100.0%Ryan Deschner of UBS Group specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY8 companies57.1%PHARMACEUTICALS6 companies42.9% Ryan Deschner's Ratings History at UBS Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsVERAVera Therapeutics11/6/2026Set Price Target$28.29$87.00$0.0000.00% ROISPRYARS Pharmaceuticals11/6/2026Downgrade$2.65Outperform$0.0000.00% ROIDNTHDianthus Therapeutics11/5/2026Reiterated Rating$85.81$134.00Strong-Buy$0.0000.00% ROIMIRMMirum Pharmaceuticals11/4/2026Reiterated Rating$87.03$189.00Strong-Buy$0.0000.00% ROIVERAVera Therapeutics10/26/2026Reiterated Rating$27.99Strong-Buy$0.0000.00% ROIPVLAPalvella Therapeutics10/16/2026Set Price Target$120.55$226.00$0.0000.00% ROILQDALiquidia10/8/2026Reiterated Rating$28.02Outperform$0.0000.00% ROILQDALiquidia10/1/2026Downgrade$30.26$53.00Outperform$0.0000.00% ROIVERAVera Therapeutics9/15/2026Reiterated Rating$35.52Strong-Buy$0.0000.00% ROIACOGAlpha Cognition7/10/2026Initiated Coverage$8.52$20.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ACOGAlpha Cognition7/10/2026Initiated Coverage$8.41$20.00Outperform$0.0000.00% ROITVRDTvardi Therapeutics7/8/2026Upgrade$3.10$10.00Outperform$0.0000.00% ROIADMAADMA Biologics6/10/2026Upgrade$8.48$21.00Moderate Buy$0.0000.00% ROIIFRXInflaRx5/13/2026Upgrade$2.43$9.00Strong-Buy$0.0000.00% ROIAPLSApellis Pharmaceuticals4/1/2026Downgrade$40.40Hold$0.0000.00% ROILQDALiquidia3/5/2026Reiterated Rating$34.28Strong-Buy$0.0000.00% ROIARDXArdelyx1/8/2026Reiterated Rating$7.00$19.00Strong-Buy$0.0000.00% ROIPVLAPalvella Therapeutics12/16/2025Reiterated Rating$88.98$193.00Strong-Buy$0.0000.00% ROIARDXArdelyx11/25/2025Reiterated Rating$5.50Strong-Buy$0.0000.00% ROIPVLAPalvella Therapeutics11/19/2025Upgrade$82.94$143.00Strong-Buy$0.0000.00% ROILQDALiquidia11/4/2025Reiterated Rating$25.22$47.00Strong-Buy$00.0000.00% ROITVRDTvardi Therapeutics10/14/2025Downgrade$6.69Market Perform$0.0000.00% ROIARDXArdelyx9/3/2025Initiated Coverage$6.46$14.00Strong-Buy$0.0000.00% ROIARDXArdelyx9/2/2025Upgrade$6.40Strong-Buy$0.0000.00% ROILQDALiquidia8/13/2025Boost Price Target$24.10$41.00Strong-Buy$00.0000.00% ROITRVITrevi Therapeutics8/8/2025Lower Price Target$7.13$27.00Strong-Buy$00.0000.00% ROIPVLAPalvella Therapeutics8/5/2025Set Price Target$37.52$54.00Outperform$000.0000.00% ROIARDXArdelyx8/5/2025Reiterated Rating$5.08$12.00Outperform$0.0000.00% ROIAPLSApellis Pharmaceuticals8/1/2025Lower Price Target$22.61$50.00Outperform$0.0000.00% ROIVKTXViking Therapeutics7/24/2025Lower Price Target$33.80$122.00Strong-Buy$00.0000.00% ROITVRDTvardi Therapeutics7/14/2025Initiated Coverage$27.34$62.00Outperform$0.0000.00% ROIAPLSApellis Pharmaceuticals5/9/2025Downgrade$17.88$52.00Outperform$00.0000.00% ROILQDALiquidia5/9/2025Boost Price Target$15.44$29.00Strong-Buy$00.0000.00% ROITRVITrevi Therapeutics3/10/2025Upgrade$4.30$29.00Strong-Buy$00.0000.00% ROIARDXArdelyx2/21/2025Reiterated Rating$5.29$13.00Strong-Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsRaymond James Financial Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
